# Study to Evaluate the Effects of Single Ascending Oral Doses of ACD856 on Safety, Tolerability and Pharmacokinetics

> **NCT05077631** · PHASE1 · COMPLETED · sponsor: **AlzeCure Pharma** · enrollment: 56 (actual)

## Conditions studied

- Alzheimer Disease
- Cognition Disorder

## Interventions

- **DRUG:** ACD856
- **DRUG:** Placebo
- **DRUG:** ACD856 (fed cohort)

## Key facts

- **NCT ID:** NCT05077631
- **Lead sponsor:** AlzeCure Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-02-15
- **Primary completion:** 2022-02-22
- **Final completion:** 2022-02-22
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2022-07-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05077631

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05077631, "Study to Evaluate the Effects of Single Ascending Oral Doses of ACD856 on Safety, Tolerability and Pharmacokinetics". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05077631. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*